4/10/2017. Agenda. Overview: Biomarker Industry. + Industry Overview + Biomarker Labs Overview + Biomarker Intended Use and Challenges
|
|
- Horatio Eaton
- 5 years ago
- Views:
Transcription
1 Agenda Placement of Biomarker Analysis in a CLIA or Laboratory + Industry Overview + Biomarker Labs Overview + Biomarker Intended Use and Challenges Patrick Bennett, PPD Panel Discussion 29 March 2017 Overview: Biomarker Industry 1
2 Biomarker Analytical Laboratories Pharma Decision Making for Biomarker Project Pharma Decision Making for Biomarker Project Early Development Clinical Development Post-Approval Preclinical Development Phase I Phase II Phase III Regulatory Filing/ Approval Safety and Surveillance Qualified Vendor Lab Geographical Constraints Lab Selection Specialty Testing Lab Biomarkers Lab Capacity & Timing Capability, Platform & Experience Restart at Step 4? Academic/Research Institute Lab Type of Laboratory Pricing Commercial Clinical Lab/Hospital Central Lab Compliance Intended Use Qualified Vendor 4 2
3 Internal CRO Decision Making for Biomarker Project Industry Structure Comparison Biomarker Intended Use Laboratory Type Compliance Lab Selection Geographical constraints Capacity Capability Biomarker Labs Overview + Pharma/Biopharma: + Discovery + DMPK/ + Outsourcing & Procurement + CRO: + group + LC/MS + LBA + University: + Research + Clinical + Pharma/Biopharma + Translational, Biomarker + DMPK/ + CRO + + Central Labs + Specialty Labs + University/Medical + Commercial + Clinical Diagnostics + Companion Diagnostics + Other Vendors 9 3
4 Industry Challenges for Biomarkers Industry Challenges for Biomarkers Biomarker Lab Perspectives Pharma/Biopharma + +Translational Sciences + Biomarker + Clinical + Outsourcing & Procurement CRO + Preclinical/Toxicology based + Clinical based + group + LC/MS + Ligand Binding Assay + Central Lab + LC/MS + Ligand Binding Assay + Flow Cytometry + Clinical Chemistry + Immunohistochemistry + Anatomical Pathology + Clinical Diagnostic & Hospital + Medical + University + Research + Medical +Specialty Lab + Anatomical Pathology + ICH + Molecular genomics + Proteomics + Metabolomics + Other omics Academia & Research Institute Preclinical & Toxicology CRO Full Service Clinical CRO CRO Diagnostic & Medical Lab Compliance Perspectives Study Logistics Perspectives Reporting Perspectives Various Various Various Strong GLP focus Short Term Study/Protocol Based Strong Compliance, CLIA & CAP, GCLP, GLP CLIA & CAP, IVD, RUO Short and Long Term Immediate Vendors 510K, IVD, RUO Immediate & Future Central Labs: Patient based Labs: Study/protocol based Patient based NA
5 Biomarker Intended Use & Challenges Comparing Characteristics & Intended Use + Dosed + Quantitative, Qualitative or both + Determine drug concentration in biological matrix + ADME + Toxicology + Safety & Efficacy + Pharmacokinetics + Drug-Drug Interactions + Drug metabolites + Immunogenicity Biomarker + Endogenous analyte + Quantitative, Qualitative or both + Measurement or characterization in a biological matrix related to intended use + Up/down-regulated + Activity + Predictive, diagnostic, prognostic, theranostic, pharmacodynamic + Patient selection or stratification + Exposure + Safety/efficacy + Mechanism of action + Specific vs. pathway + Actual or surrogate endpoint Use of Biomarker Data +Decision Making CLIA/CAP Exploratory Fit for Purpose GCLP/GLP Medical/Diagnostic Related Inclusion: Analyte 1 Medical Monitoring: Analyte 2 Efficacy Primary Endpoint Analyte 3 Secondary Endpoint Analyte 4 Drug Development Related Analyte 5 Analyte 6 Analyte
6 Use of Biomarker Data & Challenges Assay Challenges Comparison Biomarker Assay Challenges: Study Design +Medical/Diagnostic Based: + Patient selection: rapid turnaround time, global implementation + Safety: rapid turnaround time, global implementation + Per Time point or Patient reporting + Informed Consent Process +Drug Development Based + Method validation/compliance/sample analysis and reporting varies based on use of the data + Retrospective analysis + Quality of standardization of sample collection, processing or curation. + Informed Consent Process +Pre-analytical Factors + Study Design + Compliance +Analytical Factors + Compliance + Method Development & Validation + Data Processing & Reporting + Study based Biomarker + Pre-analytical Factors + Study Design + Compliance + Test selections + Laboratory selections + Geography + Analytical Factors + Compliance decisions per analyte + Method Development & Qualification/Validation + Data Processing & Reporting + Study & sample/patient based +Range of samples/time point possible for each study +Shared samples for many biomarkers +Healthy Vs Diseased performance differences +Potentially different locations, labs, companies, instrumentation, methodology and SOPs +Potential different Normal Values +Sample collection, processing and shipping timing and issues +Matrix selection & volumes +Geographic Locations
7 Thank You! 7
Placement of Biomarker Analysis in a CLIA or Bioanalytical Laboratory
Placement of Biomarker Analysis in a CLIA or Bioanalytical Laboratory Patrick Bennett, PPD Panel Discussion 29 March 2017 Agenda + Industry Overview + Biomarker Labs Overview + Biomarker Intended Use and
More informationbioanalytical challenge Patrick Bennett PPD Biomarker Laboratories November 2015
Biomarkers: Not just another bioanalytical challenge Patrick Bennett PPD Biomarker Laboratories a o November 2015 European Bioanalysis Forum 1 Biomarker Life Cycle Discovery Preclinical... Clinical Testing
More informationSpecialty Lab Services. Deep science at scale
Specialty Lab Services Deep science at scale Advancing biomarker research Our broad expertise and global laboratory footprint deliver deep science at scale Specialty assays drive insight into preclinical
More informationSHORT COURSE. Practical Considerations for Biomarker Bioanalysis: Scientific and Regulatory Perspective SUNDAY, SEPTEMBER 17
SHORT COURSE SUNDAY, SEPTEMBER 17 OMNI PROVIDENCE HOTEL PROVIDENCE, RI Practical Considerations for Biomarker Bioanalysis: Scientific and Regulatory Perspective SPONSORED BY: Organized by: www.bostonsociety.org
More informationPPD LABORATORIES COMPREHENSIVE SERVICES
PPD LABORATORIES COMPREHENSIVE SERVICES PPD_Comprehensive_Brochure2016_SinglePages_FINAL.indd 1 6/9/2016 6:04:02 PM PPD LABORATORIES: GLOBAL INNOVATIVE PROVEN PPD Laboratories combines world-class scientific
More informationExplore the World of End-to-End. Integrated Lab Performance
Explore the World of End-to-End Integrated Lab Performance Come explore the largest, wholly owned network of BioPharma dedicated laboratories in the world. Discovery/Pharmacology Pre-Clinical/Early Development
More informationPAREXEL GENOMIC MEDICINE SERVICES. Applying genomics to enhance your drug development journey
PAREXEL GENOMIC MEDICINE SERVICES Applying genomics to enhance your drug development journey YOUR JOURNEY. OUR MISSION. Genomic expertise to simplify the route to product approval and maximize patient
More informationAgreed with W. Cornell Graduate Program and Tri-I
Drug Development Course From Molecule to Prescription Weill Cornell Graduate School - Tri-Institutional Therapeutics Discovery Institute ABOUT THIS COURSE This course has been designed in collaboration
More informationChallenges in developing Biomarker Assays for patient selection and Companion Diagnostic (CDx) Assays in early and late stage of drug development
Challenges in developing Biomarker Assays for patient selection and Companion Diagnostic (CDx) Assays in early and late stage of drug development The 9 th JBF Symposium February 8 th, 2018 Kenji Nakamaru
More informationTECHNOLOGIES & SERVICES FOR THERAPEUTIC ANTIBODY DEVELOPMENT
Specialist in tissue analysis by Histology, Immunohistochemistry and In Situ Hybridization TECHNOLOGIES & SERVICES FOR THERAPEUTIC ANTIBODY DEVELOPMENT CONTENTS Histalim: who we are Our areas of expertise
More informationMaximizing opportunities towards achieving clinical success D R U G D I S C O V E R Y. Report Price Publication date
F o r a c l e a r e r m a r k e t p e r s p e c t i v e Early Stage Drug Safety Strategies & Risk Management Maximizing opportunities towards achieving clinical success D R U G D I S C O V E R Y Report
More informationICH Topic E16 Genomic Biomarkers Related to Drug Response: Context, Structure and Format of Qualification Submissions. Step 3
European Medicines Agency June 2009 EMEA/CHMP/ICH/380636/2009 ICH Topic E16 Genomic Biomarkers Related to Drug Response: Context, Structure and Format of Qualification Submissions Step 3 NOTE FOR GUIDANCE
More informationReflection paper on co-development of pharmacogenomic biomarkers and Assays in the context of drug development
1 2 3 24 June 2010 EMA/CHMP/641298/2008 Committee for Medicinal Products for Human Use (CHMP) 4 5 6 7 Reflection paper on co-development of pharmacogenomic biomarkers and Assays in the context of drug
More informationCRYSTAL CITY V REDUX: GUIDANCE FOR INDUSTRY BIOANALYTICAL METHOD VALIDATION DRAFT GUIDANCE (2013) VI. ADDITIONAL ISSUES
CRYSTAL CITY V REDUX: GUIDANCE FOR INDUSTRY BIOANALYTICAL METHOD VALIDATION DRAFT GUIDANCE (2013) VI. ADDITIONAL ISSUES DELAWARE VALLEY DRUG METABOLISM DISCUSSION GROUP STEVE PICCOLI, BMS RAND JENKINS,
More informationMay 23, :30 PM-5:00 PM - AUDITORIUM A250. May 9, :30 PM -5:00 PM - AUDITORIUM A-950 May 16, :30 PM-5:00 PM - AUDITORIUM A250
DRUG DEVELOPMENT COURSE - FROM MOLECULE TO PRESCRIPTION WEILL CORNELL GRADUATE SCHOOL - TRI-INSTITUTIONAL THERAPEUTICS DISCOVERY INSTITUTE THURSDAYS FROM 3:00PM - 5:00PM AT 1300 YORK AVE, NEW YORK, N.Y.
More informationYour bridge to. better medicines
Your bridge to better medicines At a Glance Anapharm Bioanalytics is a client-oriented, GLP-certified, FDA-inspected, GCP-compliant and ANVISA-certified bioanalytical contract research organization (CRO)
More informationConsiderations for Successful Biomarker Bioanalysis in Regulated Environment
Considerations for Successful Biomarker Bioanalysis in Regulated Environment Darshana Jani, M.Sc. Darshana.Jani@pfizer.com 10 th European Bioanalysis Forum November 15, 2017 1 Disclaimer The contents of
More informationAdvancing utility and adoption of clinical genomic diagnostics
Advancing utility and adoption of clinical genomic diagnostics Laura J. van t Veer Director Applied Genomics, Program Leader Breast Oncology Helen Diller Family Comprehensive Cancer Center University of
More informationCase Studies on ultra-sensitive immunoanalytics based on Imperacer (Immuno-PCR) in clinical settings. Jan Detmers, Ph.D. (Chimera Biotec GmbH)
Case Studies on ultra-sensitive immunoanalytics based on Imperacer (Immuno-PCR) in clinical settings. Jan Detmers, Ph.D. (Chimera Biotec GmbH) Agenda 1.Overview Platforms 2.Immuno-PCR (Imperacer ) Technology
More informationAn Introduction to Clinical Research and Development
Bay Clinical R&D Services An Introduction to Clinical Research and Development The Complex Process by which New Drugs are Tested in Humans Anastassios D. Retzios, Ph.D. Outline of Presentation What is
More informationCelerion s Symposia Series: Bridging the Gap from Phase I to Proof-of-Concept. San Francisco, CA Tue 8 th, Apr 2014
Celerion s Symposia Series: Bridging the Gap from Phase I to Proof-of-Concept San Francisco, CA Tue 8 th, Apr 2014 Mind the Gap: Elements of a Bridging Strategy J. Fred Pritchard, Ph.D. Vice President,
More information"From Bedside to Bench and Back: regulatory requirements for collaborations between pharma industry and academia
"From Bedside to Bench and Back: regulatory requirements for collaborations between pharma industry and academia Damir Hamamdžić D.V.M., Ph.D. Office of Research Regulatory Affairs Rutgers University RWJMS
More informationBy: Augustine Onyeaghala Clinical Research/Quality Management Systems Consultant Global Health Trial Workshop Lagos,
By: Augustine Onyeaghala Clinical Research/Quality Management Systems Consultant Global Health Trial Workshop Lagos, Email: aonyeaghala@ymail.com. Understand different regulations governing laboratory
More informationBiomarker Regulation. Regulator s perspective. Jan Müller-Berghaus
www.pei.de Biomarker Regulation Regulator s perspective Jan Müller-Berghaus The views presented here are my own and do not necessarily reflect the views of the Paul-Ehrlich-Institut or any other regulatory
More informationOverview of Biomarker Qualification. Marc K Walton MD, PhD Office of Translational Sciences CDER-FDA
Overview of Biomarker Qualification Marc K Walton MD, PhD Office of Translational Sciences CDER-FDA Categories of Biomarkers Prognostic Predictive Pharmacodynamic Including adverse response Efficacy-response
More informationIndustry Academic Collaboration: A Key to Successful Involvement of Patients Early in Clinical Development
Industry Academic Collaboration: A Key to Successful Involvement of Patients Early in Clinical Development Aernout van Haarst PhD Director, European Corporate Development Feb 2016 Industry Academic Collaboration
More informationTechnical Assessment (TA) Summary Form (M00116)
Technical Assessment (TA) Summary Form (M00116) Please complete the following 2 table summarization of the dossier. Table 1. Summary of Evidence Validation Element For each cell below, please provide the
More information"Stratification biomarkers in personalised medicine"
1/12 2/12 SUMMARY REPORT "Stratification biomarkers in personalised medicine" Workshop to clarify the scope for stratification biomarkers and to identify bottlenecks in the discovery and the use of such
More informationCurrent Best Practices in Commercial Kit Evaluation and Validation for Biomarker Assays
Current Best Practices in Commercial Kit Evaluation and Validation for Biomarker Assays 10th Workshop on Recent Issues in Bioanalysis, 2016 Paul Rhyne, Ph.D. - Director of Immunoassay Services Copyright
More informationIntegration of FDSS7000 into a modular robotic system for Open Innovation drug discovery
Integration of FDSS7000 into a modular robotic system for Open Innovation drug discovery José Manuel Brea & María Isabel Loza BioFarma, Santiago de Compostela DRUG DISCOVERY OPEN INNOVATION CLOSED innovation
More informationDMTC Technology Readiness Levels Guideline
Technology Readiness Levels Technology Readiness Levels (TRLs) are used as standardised numerical indicators of the level of maturity of a technology. The standard TRL definitions are given in Table 1.
More informationMRC Stratified Medicine Initiative
MRC Stratified Medicine Initiative Jonathan Pearce Medical Research Council, Translational Programme Manager Pharmacogenetics and Stratified Medicine Network Conference : 14 th January 2015 Stratified
More informationTechnical Guidance on Development of In Vitro Companion Diagnostics and Corresponding Therapeutic Products
Administrative Notice December 26, 2013 To: Division of Pharmaceutical Affairs, Prefectural Health Department (Bureau) From: Evaluation and Licensing Division, Pharmaceutical and Food Safety Bureau Ministry
More informationDate/Lecturer Class Topic Readings 01/28/10 Brookman
Course Director: Sheldon, Ph.D. 01/28/10 1 I. Course Description and Requirements II. Historical Perspectives and Overview of Drug Development a. Evolution of the pharmaceutical industry b. Changing development
More informationCapabilities & Services
Capabilities & Services Accelerating Research & Development Table of Contents Introduction to DHMRI 3 Services and Capabilites: Genomics 4 Proteomics & Protein Characterization 5 Metabolomics 6 In Vitro
More informationStart With the End in Mind A Diagnostic Company s Perspective on Companion Diagnostic Development. Paul Docherty PhD Relationship Management
Start With the End in Mind A Diagnostic Company s Perspective on Companion Diagnostic Development Paul Docherty PhD Relationship Management Disclaimer This presentation contains my personal views and research
More informationKPI Definition Comment Relates to Baseline Target
IMI2 Key performance indicators (KPIs) Reporting on measuring and outcomes on the ten following Key Performance Indicators will be provided yearly as part of the IMI2 JU Annual Activity Reports for year
More informationLAB EXPERTS AT YOUR SIDE Over twenty years of experience
LAB EXPERTS AT YOUR SIDE Over twenty years of experience About us SYNLAB Pharma offers a broad range of laboratory services to the biotechnology, pharmaceutical and cosmetic industries as well as to manufacturers
More informationSuccessful transfer of ligand binding assays between different laboratories
Successful transfer of ligand binding assays between different laboratories Debbie McManus Team Leader, Department of Biomarkers, Bioanalysis and Clinical Sciences 10 th EBF Open Symposium Hesperia Tower,
More informationENTREPRENEURIAL OPPORTUNITIES IN LIFE SCIENCE QUALITY & REGULATORY
BIOANALYTICAL SOLUTIONS FOR BIOTHERAPEUTICS AND SMALL MOLECULE THERAPEUTICS ENTREPRENEURIAL OPPORTUNITIES IN LIFE SCIENCE QUALITY & REGULATORY MARCH 15, 2017 AIT BIOSCIENCE, LLC BIOANALYSIS TO SUPPORT
More informationThe Right Molecules. Designed. Delivered.
The Right Molecules. Designed. Delivered. 400+ Worldwide Clients 80+ Medicinal Chemistry Programs 20+ Preclinical Candidates Delivered Since 2008 10+ In IND Stage 5 Entered Phase I Clinical Trials 2 Entered
More informationPersonalized Medicine A new challenge for applied human pharmacology?
Personalized Medicine A new challenge for applied human pharmacology? Jochen Theis, MD FFPM InHeCon Leipzig 2 nd March 2012 Personalized Medicine: Predicting Variability in Drug Response InHeCon Jochen
More informationChallenges for Flow Cytometry in Regulated Bioanalysis
Challenges for Flow Cytometry in Regulated Bioanalysis Minesh Patel Merck Millipore Discovery & Development Solutions. Oxford, UK. Overview Flow cytometry principles Current uses and regulatory environments
More informationUsing Ligang-Binding Assay Sensitivity for Improved Matrix Tolerance and Related Parameters by Tailored Sample Dilution.
Using Ligang-Binding Assay Sensitivity for Improved Matrix Tolerance and Related Parameters by Tailored Sample Dilution. Dr. Mark Spengler, Chimera Biotec Chimera Biotec Company Overview Bioanalytical
More informationQualifying SPR immunogenicity assays Dr. Christian Kühne
Qualifying SPR immunogenicity assays Dr. Christian Kühne Bioagilytix / IPM Biotech global CRO for large molecule bioanalysis supporting pre-clinical & clinical studies Biomarker, Pharmacokinetics, Immunogenicity
More informationThe Intersection of Genomics Research and the IDE Regulation
The Intersection of Genomics Research and the IDE Regulation Katherine Donigan, Ph.D. Personalized Medicine Staff FDA/CDRH/OIR October 19, 2017 1 In Vitro Diagnostic (IVD) Regulation Through the 1976 medical
More informationCDRH Device Approval
CDRH Device Approval Mary S. Pastel, ScD Deputy Director for Radiological Health Office of In Vitro Diagnostics and Radiological Health (OIR) Center for Devices and Radiological Health (CDRH) US Food and
More informationConsortia-Based Strategies in Neurodegenerative Diseases: Critical Path Institute s Track Record in Collaborative Efforts
Consortia-Based Strategies in Neurodegenerative Diseases: Critical Path Institute s Track Record in Collaborative Efforts Martha A. Brumfield, PhD President & CEO Agenda C-Path Model for Collaboration
More informationCENTRAL NERVOUS SYSTEM (CNS) BIOMARKERS: TECHNOLOGIES AND GLOBAL MARKETS
CENTRAL NERVOUS SYSTEM (CNS) : TECHNOLOGIES AND GLOBAL MARKETS BIO074C March 2016 Jackson Highsmith Project Analyst ISBN: 1-62296-246-X BCC Research 49 Walnut Park, Building 2 Wellesley, MA 02481 USA 866-285-7215
More informationFast Track Drug Development The Clinical (Caleidoscopic) Perspective
20 Years AGAH, Annual Meeting, Hamburg 21.-23. February 2010 Fast Track Drug Development The Clinical (Caleidoscopic) Perspective Fritz R. Bühler, MD ECPM, University of Basel European Innovative Medicine
More information! Background. ! What is really new?! The new Section 7: Explorative Clinical Trials (ECTs) ! Consequences in General
! Background! What is really new?! The new Section 7: Explorative Clinical Trials (ECTs)! 5 Approaches (Table 3) for:! Microdose trials (7.1)! Single-Dose (SD) Trials at Sub-therapeutic Doses or Into the
More informationThe Journey Towards Standardization in Validation of Fluorescent Cell-Based Assays
The Journey Towards Standardization in Validation of Fluorescent Cell-Based Assays Teri Oldaker, CLS, Ccy Genoptix Medical Laboratory Flow Cytometry Workshop ISCT 2015, Las Vegas, NV Objectives Background
More informationImpact of clinical trial design on potential IVD regulatory claims
Impact of clinical trial design on potential IVD regulatory claims Claudia Dollins, PhD RAC Head Global Regulatory Affairs, Biomarkers & Diagnostics Merck KGaA Merck KGaA Darmstadt, Germany Disclaimer
More informationCorrelative Science and Tissue Banking Procedures. Canadian Cancer Trials Group
Correlative Science and Tissue Banking Procedures Canadian Cancer Trials Group January 31, 2013 Our Policy The Canadian Cancer Trials Group has established a tumour/tissue/data repository to ensure the
More informationNovartis Business Services HR University Relations. Clinical Sciences and Innovation. Postgraduate Program
Novartis Business Services HR University Relations Clinical Sciences and Innovation Postgraduate Program 2 CLINICAL SCIENCES AND INNOVATION CLINICAL SCIENCES AND INNOVATION 3 The CS&I Postgraduate Program
More informationSMCxPRO Immunoassay System Sensitivity You Can Count On
SMCxPRO Immunoassay System Sensitivity You Can Count On The life science business of Merck operates as MilliporeSigma in the U.S. and Canada. Fit for Your Purpose Protein detection at every level. Your
More informationForthcoming Calls for Proposals (10/11) Barcelona 28 June 2013
Forthcoming Calls for Proposals (10/11) Barcelona 28 June 2013 Indicative list Proposed topic /11 /11 /11 Identification and validation of innovative clinical endpoints for Osteoarthritis European genotype-phenotype
More informationABF Pharmaceutical Services GmbH
ABF Pharmaceutical Services GmbH Facts and Figures GBA is a European laboratory group with an annual turnover of +40 M. Founded in 1989, Hamburg Our business covers Pharma, Environmental, Foodstuff, Consumer
More informationDiagnostics in Oncology Mark Kockx MD, PhD
HistoGeneX The Real World A Specialized of companion Biomarker & Integrated Pathology Laboratory Diagnostics in Oncology Mark Kockx MD, PhD 1 2 HistoGeneX located in Antwerp, Belgium and Chicago, Illinois
More informationSuccessful Academia-Pharma Collaboration Drug Discovery and Clinical Development
Successful Academia-Pharma Collaboration Drug Discovery and Clinical Development Toshio MIYATA Tohoku University Graduate School of Medicine United Centers for Advanced Research and Translational Medicine
More informationFDA Regulation of Companion Diagnostics
FDA Regulation of Companion Diagnostics Paul Radensky October 11, 2017 Disclosure + Slideset drawn from Part I of presentation made by Janice Hogan, HoganLovells, October 2016 + Updated where appropriate
More informationthe biomarker testing laboratory
the biomarker testing laboratory RBM, the industry leader in comprehensive, multiplexed immunoassay testing services, delivers high-quality, reproducible biomarker results by industrializing the measurement
More informationRoche, Roche Molecular Diagnostics and more
, Molecular and more [Monte Wetzel, PhD] Patients have questions. We provide answers. Group Clear focus on Healthcare Innovation with two strong pillars Pharma Pharma Genentech Chugai Molecular Professional
More informationIssues in Cancer Drug Development of the Future. Janet Woodcock M.D. Deputy Commissioner/Chief Medical Officer, FDA October 5, 2007
Issues in Cancer Drug Development of the Future Janet Woodcock M.D. Deputy Commissioner/Chief Medical Officer, FDA October 5, 2007 Agenda: Scientific Issues n Why improve the quality of cancer clinical
More informationIntroduction to Drug Design and Discovery
Introduction to Drug Design and Discovery Course: Drug Design Course code: 0510412 Dr. Balakumar Chandrasekaran Dr. Bilal Al-Jaidi Assistant Professors, Pharmaceutical Medicinal Chemistry, Faculty of Pharmacy,
More information227 AP and >100 CDx engagements
Anatomic pathology Q 2 Solutions comprehensive in-house end-to-end anatomic pathology and adjunct molecular services are designed to meet your clinical trial needs. Anatomic pathology is a vital part of
More informationOptimisation de votre programme de développement
Optimisation de votre programme de développement Cedric Lamy, PhD. Cedric.lamy@crl.com Charles River Overview 65-year history: Founded in 1946, publicly traded (NYSE:CRL) Investment in skilled staff: ~7,500
More informationBiomarker Utility and Acceptance in Drug Development and Clinical Trials: an FDA Regulatory Perspective
Biomarker Utility and Acceptance in Drug Development and Clinical Trials: an FDA Regulatory Perspective Chris Leptak, MD/PhD OND Biomarker and Companion Diagnostic Lead CDER/Office of New Drugs, Immediate
More informationComments from the FDA Working Group on SUBGROUP ANALYSES. Estelle Russek-Cohen, Ph.D. U.S. Food and Drug Administration Center for Biologics
Comments from the FDA Working Group on SUBGROUP ANALYSES Estelle Russek-Cohen, Ph.D. U.S. Food and Drug Administration Center for Biologics 1 Outline An intro to FDA EMA and FDA on subgroups Companion
More informationFirst Annual Biomarker Symposium Quest Diagnostics Clinical Trials
First Annual Biomarker Symposium Quest Diagnostics Clinical Trials Terry Robins, Ph.D. Director Biomarker R&D and Scientific Affairs Quest Diagnostics Clinical Trials Key Considerations: Biomarker Development
More informationCommon BA/BE Inspection Observations and Scientific Evaluation
Common BA/BE Inspection Observations and Scientific Evaluation Ruben C. Ayala, Pharm.D. Lead Pharmacologist Division of New Drug Bioequivalence Evaluation Office of Study Integrity and Surveillance (OSIS)
More informationBIOSTATISTICAL METHODS FOR TRANSLATIONAL & CLINICAL RESEARCH
BIOSTATISTICAL METHODS FOR TRANSLATIONAL & CLINICAL RESEARCH Phase 0 Trials: EARLY-PHASE CLINICAL TRIALS CLINICAL PHASE Clinical Studies: Class of all scientific approaches to evaluate Disease Prevention,
More informationBIOSTATISTICAL METHODS
BIOSTATISTICAL METHODS FOR TRANSLATIONAL & CLINICAL RESEARCH Phase 0 Trials: EARLY-PHASE CLINICAL TRIALS Steps to New Drug Discovery Get idea for drug target Develop a bioassay Screen chemical compounds
More informationIntroduction to clinical trials Magnus Kjaer
Introduction to clinical trials 2016-01-20 Magnus Kjaer One Definition of Clinical Trial NIH 2014 A research study in which one or more human subjects are prospectively assigned to one or more interventions
More informationApplication of PGx in PK at FDA: Experience and Expectations
Application of PGx in PK at FDA: Experience and Expectations EMEA-EFPIA Workshop Integrating PGx into Early Drug Development London UK 19 December 2008 Lawrence J. Lesko, Ph.D., F.C.P. Office of Clinical
More informationComplex Adaptive Systems Forum: Transformative CAS Initiatives in Biomedicine
Complex Adaptive Systems Forum: Transformative CAS Initiatives in Biomedicine January 18, 2013 Anna D. Barker, Ph.D. Director, Transformative Healthcare Networks C-Director, Complex Adaptive Systems Initiative
More informationPreanalytical Processing: The Biospecimen Quality Imperative
Preanalytical Processing: The Biospecimen Quality Imperative Carolyn Compton, MD, PhD Chair, Scientific Advisory Committee, Indivumed GmbH Professor of Life Sciences, ASU Professor of Laboratory Medicine
More informationIn Vitro Companion Diagnostic Devices
4 th of Joint Conference of Taiwan and Japan on Medical products regulation In Vitro Companion Diagnostic Devices 2016/12/7 Aoyagi Yumiko Ministry of Health, Labour and Welfare Medical Device Evaluation
More informationPaving the way for Non-Clinical Bioanalytical Partnerships Louise Angell
Paving the way for Non-Clinical Bioanalytical Partnerships Louise Angell Content Overview of non-clinical immunogenicity testing for biologics Regulatory guidance Bioanalytical considerations Risk based
More informationIntroducing a Highly Integrated Approach to Translational Research: Biomarker Data Management, Data Integration, and Collaboration
Introducing a Highly Integrated Approach to Translational Research: Biomarker Data Management, Data Integration, and Collaboration 1 2 Translational Informatics Overview Precision s suite of services is
More informationRegulatory Issues and Drug Product Approval for Biopharmaceuticals
Regulatory Issues and Drug Product Approval for Biopharmaceuticals Vinod P. Shah, Ph. D. FIP Scientific Secretary Biotech 2007 Southern African Regional and International Regulatory Biotechnology Workshop
More informationStructure and Mandate of FDA
Structure and Mandate of FDA Leonard Sacks, M.D. Office of Medical Policy Center for Drug Evaluation and Research FDA FDA Clinical Investigator Training Course November 13, 2018 Mission of regulatory agencies
More informationThe Irish Biomarker Network - Inaugural Workshop Improved Translation of Biomarkers to the Clinic
The Irish Biomarker Network - Inaugural Workshop Improved Translation of Biomarkers to the Clinic 1 The Irish Biomarker Network -Inaugural Workshop Improved Translation of Biomarkers to the Clinic Overview
More informationBIOMARKERS: TECHNOLOGIES AND GLOBAL MARKETS
: TECHNOLOGIES AND GLOBAL MARKETS BIO061C April 2014 Jackson Highsmith Project Analyst ISBN: 1-56965-801-3 BCC Research 49 Walnut Park, Building 2 Wellesley, MA 02481 USA 866-285-7215 (toll-free within
More informationUniversity joins Industry: Clinical Trials & Drug Safety. Aula Magna-Facultad de Farmacia 11 Marzo 2015
University joins Industry: Clinical Trials & Drug Safety Aula Magna-Facultad de Farmacia 11 Marzo 2015 Contents Background, key points and basic knowledge Department tasks and responsibilities Importance
More informationPATHWAYS TO BIOMARKER QUALIFICATION AND ACCEPTANCE
PATHWAYS TO BIOMARKER QUALIFICATION AND ACCEPTANCE CHRISTOPHER LEPTAK, M.D., PH.D. DIRECTOR, OND REGULATORY SCIENCE PROGRAM CO-DIRECTOR, BIOMARKER QUALIFICATION PROGRAM NASH Biomarkers Workshop May 5,
More informationApril transmart v1.2 Case Study for PredicTox
April 2015 transmart v1.2 Case Study for PredicTox Agenda Agenda! What is PredicTox?! Brief transmart overview! Answering scientific questions with transmart s help: A case study maximizing data value!
More informationKey Resources in Biomedical Product Development
Key Resources in Biomedical Product Development Suguna Rachakonda - June 7, 2017 1 Business Model - Definition What does it mean to have a Business Model? A business model describes the rationale of how
More informationClinical Trial Outsourcing: A Case Study For Small Biotechnology Companies Operating Globally
Clinical Trial Outsourcing: A Case Study For Small Biotechnology Companies Operating Globally Cerus Corporation Concord, CA Laurence Corash, MD Chief Medical Officer Meisa Propst, Associate Director Clinical
More informationThe Five Key Elements of a Successful Metabolomics Study
The Five Key Elements of a Successful Metabolomics Study Metabolomics: Completing the Biological Picture Metabolomics is offering new insights into systems biology, empowering biomarker discovery, and
More informationTerminology for personalized medicine
Terminology for personalized medicine Sarah Ali-Khan 1 PhD, Stephanie Kowal 2, Westerly Luth 2, Richard Gold 1 SJD, and Tania Bubela 2 PhD JD 1. Centre for Intellectual Property Policy (CIPP), Faculty
More informationBiomarker Assay Translation from Discovery to Clinical Studies in Cancer Drug Development: Quantification of Emerging Protein Biomarkers
Biomarker Assay Translation from Discovery to Clinical Studies in Cancer Drug Development: Quantification of Emerging Protein Biomarkers Jean W. Lee,* Daniel Figeys, { and Julian Vasilescu { *Amgen Inc.,
More informationIntegrating an exploratory BM in an early clinical stage in Pharma R&D
Integrating an exploratory BM in an early clinical stage in Pharma R&D Ulrich Kunz, Translational Medicine and Clinical Pharmacology, Boehringer Ingelheim Pharma GmbH & Co. KG, Biberach, Germany Content
More informationIntroduction to clinical trials
Introduction to clinical trials Definition of a clinical trial A research activity that involves administration of a test treatment to some experimental unit in order to evaluate the treatment. Key words
More informationFit-for-Purpose Biomarker Assay Validation: From Concept to Practices
Fit-for-Purpose Biomarker Assay Validation: From Concept to Practices Jean Lee, Ph.D., FAAPS Consultant BioQualQuan, LLC 6 th Japan Bioanalysis Forum Symposium February 25, 2015 Outline of discussions
More informationBIOPHARMA SOLUTIONS TM Expedite Your Drug Development Program
BIOPHARMA SOLUTIONS TM Expedite Your Drug Program Maximize the Value of Your Asset The journey of drug development can be complex stressful. But it doesn t have to be that way. Join more than 600 biopharmaceutical
More informationPublic private partnerships in support to regulatory sciences
Public private partnerships in support to regulatory sciences The Innovative Medicines Initiative example M. Chlebus 3 October 2017 www.efpia.eu Summary: Partnering on regulatory sciences Progress much
More informationAssociation for Molecular Pathology Promoting Clinical Practice, Basic Research, and Education in Molecular Pathology
Association for Molecular Pathology Promoting Clinical Practice, Basic Research, and Education in Molecular Pathology 9650 Rockville Pike, Bethesda, Maryland 20814 Tel: 301-634-7939 Fax: 301-634-7990 Email:
More informationCRED: Understanding Clinical Development Programme June 2018 Day one Chairperson: Steve Pinder, Envestia Ltd
CRED: Understanding Clinical Development Programme 27-28 June 2018 Day one Chairperson: Steve Pinder, Envestia Ltd Time Activity Speaker 09.20 Registration and Coffee 09.30 Introduction to TOPRA 09.35
More informationLessons Learned: Bringing diagnostics to market in low and middle income countries
Lessons Learned: Bringing diagnostics to market in low and middle income countries Workshop on New & Innovative Approaches to Laboratory Diagnosis of Zika, Dengue & Other Arboviruses PDC, Fondation Merieux,
More information